Pfizer receives EU approval for Trazimera(Trastuzumab)- the First Oncology Biosimilar
Shots:
- Trazimera is a biosimilar of Herceptin indicated for treatment of HER2 overexpressing breast cancer and metastatic gastric or gastroesophageal junction adenocarcinoma
- The EC approval is based on the data including REFLECTION B327-02 clinical study showing similarity b/w Trazimera and original product in patient
- Trazimera has been studied in ~500 patients across 20 countries
Ref: Pfizer | Image: Business wire
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com